Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Irwin Walker, Uday Deotare, Mohamed Elemary, Mahmoud Elsawy, Genevieve Gallagher, David Kliman, Tony Panzarella, Nada Hamad, Kirk R. Schultz, Jan Storek, Kristjan Paulson

Blood (2024) 144 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2024-198798

Published: 2024

Journal Articles

Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Andree-Anne Pelland, Xavier Savard, Frederic Barabe, Vincent Laroche, Michaël Munger, Genevieve Gallagher, Nicolas Marcoux, Guy Cantin, Maxime Chénard-Poirier, Robert Delage, Marc Lalancette, Christopher Lemieux

Blood (2022) 140 (Supplement 1): 3304–3305.

https://doi.org/10.1182/blood-2022-170223

Published: 2022

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Chemosensitive Disease Better Predicts Outcome Than Age Following Autologous Heamatopoietic Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

Christopher Lemieux, MD, Robert Delage, MD, Guy Cantin, MD, Frederic Barabe, MD, Vincent Laroche, MD, Rémy Angers, BSc, Genevieve Gallagher, MD

Blood (2017) 130 (Supplement 1): 5530.

https://doi.org/10.1182/blood.V130.Suppl_1.5530.5530

Published: 2017

Journal Articles

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Blood (2016) 127 (24): 3082–3091.

https://doi.org/10.1182/blood-2015-09-668251

Published: 2016

Includes: Supplemental data

Journal Articles

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Irwin Walker, MBBS, Kirk R. Schultz, MD, Cynthia L. Toze, MD FRCPC, Holly Margaret Kerr, RN, BSN, John Moore, MD, David Szwajcer, MD FRCPC, Stephen Ronan Foley, MD FRCPC, John Kuruvilla, MD FRCPC, Tony Panzarella, M.Sc, Félix Couture, MD, Jean Roy, MD, Stephen Couban, MD FRCPC, Gerald Devins, PhD, Gizelle Popradi, FRCPC, MD, Stephanie J. Lee, MD MPH, Jason Tay, MD MSc, FRCPC, Thomas J. Nevill, MD FRCPC, Mohamed Elemary, MD MSc,PhD, Genevieve Gallagher, MD FRCPC

Blood (2014) 124 (21): 38.

https://doi.org/10.1182/blood.V124.21.38.38

Published: 2014

Journal Articles

Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.

Genevieve Gallagher, MD, Donna E. Hogge, MD, Thomas J. Nevill, MD, Stephen H. Nantel, MD, Michael J. Barnett, MD, John D. Shepherd, MD, Heather J. Sutherland, MD, Cynthia L. Toze, MD, Clayton A. Smith, MD, Julye C. Lavoie, MD, Kevin W. Song, MD, Donna L. Forrest, MD

Blood (2005) 106 (11): 1120.

https://doi.org/10.1182/blood.V106.11.1120.1120

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Chemosensitive Disease Better Predicts Outcome Than Age Following Autologous Heamatopoietic Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.

Email alerts

ASH Publications

American Society of Hematology

Update search

A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)

Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Chemosensitive Disease Better Predicts Outcome Than Age Following Autologous Heamatopoietic Stem Cell Transplantation in Elderly Patients with Multiple Myeloma

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3 + NK cells

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Second Solid Cancers after Allogeneic Stem Cell Transplantation: The Vancouver Experience.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only